Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
THE APEX TIMES
THE APEX TIMES
The company’s newly updated shot, adapted from its XFG program, is being rolled out with deliveries starting immediately to pharmacies and clinics.
THE APEX TIMES
BioNTech’s colorectal cancer vaccine trial collapsed in Phase 2, a setback that pressured peer stocks including Moderna and weighed on investors’ expectations for mRNA oncology programs. Pfizer, which also has a stake in mRNA vaccine development through collaborations, was reported to hold roughly flat on the day.
THE APEX TIMES
A newly released industry report projects the cytotoxic drugs market rising from $16.21 billion in 2026 to $21.06 billion by 2031, citing improving access to cancer screening and treatment, including for oral therapies and newer drug formats.
THE APEX TIMES
FDA approvals for an updated COMIRNATY COVID-19 vaccine and progress on a Lyme disease effort are giving fresh momentum to arguments that Pfizer’s next phase of growth could depend less on legacy revenue and more on newer immunology and vaccine programs.
THE APEX TIMES
The companies said the FDA has approved an updated formulation designed to better match the XFG variant, with distribution planned to begin immediately.
THE APEX TIMES
A new market analysis argues that Pfizer is emphasizing near-term savings while deferring the core question of whether its medicines are gaining traction until the end of the decade.
THE APEX TIMES
A new market commentary points to a payout ratio that can look alarming, but argues investors should focus on the underlying earnings or cash-flow pressures behind Pfizer’s dividend.
THE APEX TIMES
A new comparison of Pfizer and Abbott frames the stocks as competing dividend stories, with Pfizer tied to rebuilding growth ahead of major patent expirations and Abbott more closely associated with a steadier operating profile.
